HC Wainwright Issues Pessimistic Forecast for Zynex (NASDAQ:ZYXI) Stock Price

Zynex (NASDAQ:ZYXI) had its price target lowered by investment analysts at HC Wainwright from $15.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 298.01% from the company’s current price. HC Wainwright also issued estimates for Zynex’s Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.12) EPS and Q4 2026 earnings at ($0.12) EPS.

A number of other equities research analysts also recently issued reports on ZYXI. LADENBURG THALM/SH SH downgraded shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Royal Bank of Canada restated a “sector perform” rating on shares of Zynex in a research note on Tuesday, April 15th.

Zynex Stock Performance

Shares of ZYXI opened at $2.01 on Wednesday. The firm has a market cap of $60.76 million, a P/E ratio of 13.40 and a beta of 1.09. Zynex has a twelve month low of $1.66 and a twelve month high of $11.97. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The firm’s 50 day moving average price is $3.46 and its two-hundred day moving average price is $6.51.

Zynex (NASDAQ:ZYXI) last released its earnings results on Monday, April 28th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $26.58 million during the quarter, compared to the consensus estimate of $30.83 million. On average, analysts forecast that Zynex will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total transaction of $76,800.00. Following the completion of the transaction, the chief financial officer now owns 19,738 shares of the company’s stock, valued at $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 49.28% of the company’s stock.

Hedge Funds Weigh In On Zynex

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Zynex by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 443,020 shares of the company’s stock valued at $3,549,000 after buying an additional 17,511 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Zynex by 10.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock valued at $1,276,000 after acquiring an additional 14,820 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Zynex by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 137,362 shares of the company’s stock worth $1,100,000 after acquiring an additional 3,800 shares during the last quarter. Congress Asset Management Co. grew its stake in shares of Zynex by 4.7% in the 4th quarter. Congress Asset Management Co. now owns 121,450 shares of the company’s stock worth $973,000 after acquiring an additional 5,405 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Zynex by 2.1% in the fourth quarter. Ameriprise Financial Inc. now owns 96,813 shares of the company’s stock valued at $775,000 after purchasing an additional 1,993 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.